Lyfegen is proud to announce that Melya Hughes Crameri, PhD, has joined the company´s Advisory Board. Melya has vast expertise in the life science industry both in the United States and Europe and has worked in executive positions in multiple functional areas including fundraising, business development, strategic alliances, operations, intellectual property and licensing.

She also supported the Evolva IPO in 2009 as an executive. Melya has a PhD in Biochemistry from the University of Basel and is a European Patent Attorney and a U.S Patent Agent. She is a Board Member of the Life Sciences Hub Wales and Partner at Ventac Partners.

Melya’s extensive experience in intellectual property, the UK and US market, and early stage company development is a major asset to Lyfegen, and we are delighted to welcome her as an advisor.